Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pfizer (NY:PFE)

24.43 +0.01 (+0.04%)
Official Closing Price Updated: 7:00 PM EST, Nov 7, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Pfizer

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Market Reels from Volatility and Mixed Signals: A Deep Dive into Investor Unease
The past week, from November 1st to November 8th, 2025, has witnessed a significant shift in global market sentiment, moving decisively towards a "risk-off" stance. Investors are grappling with... 
Via MarketMinute
Topics Artificial Intelligence Bonds Economy
2 No-Brainer Dividend Stocks to Buy With $100 in November
There's no need to break the bank to get your hands on excellent dividend payers. 
Via The Motley Fool
Topics Economy World Trade
Eli Lilly Strikes a Landmark Pricing Deal With the U.S. for Its Billion-Dollar Weight Loss Drugs. Here's What This Means for Investors.
Weight loss drugs generated about $10 billion for Lilly in the most recent quarter. 
Via The Motley Fool
Topics Government
Pfizer Clinches $10 Billion Deal To Buy Obesity Drug Maker Metsera, Outbidding Novo Nordisk In Fierce Battle For Weight-Loss Market Dominance
Nvidia CEO Jensen Huang cautioned Elon Musk against underestimating the challenges of semiconductor manufacturing, saying building a chip fab like TSMC's is "extremely hard." 
Via Benzinga
Deal Dispatch: From A Founder Comeback To Billion-Dollar Bids, This Week In M&A And Bankruptcy
 
Via Benzinga
Why Novo Nordisk Stock Is Sinking This Week
The global drugmaker is facing some headwinds related to tough competition. 
Via The Motley Fool
Topics Government World Trade
The Stock Market Is Signaling a Recession. Here's How to Prepare Your Portfolio.
The financial markets are increasingly flashing warning signs that an economic recession may be on the horizon, prompting investors to re-evaluate their strategies. A confluence of indicators, from... 
Via MarketMinute
Topics Bonds Economy Stocks
Friday's session: most active stock in the S&P500 index
Explore the S&P500 index on Friday and find out which stocks are the most active in today's session. Stay updated with the stocks that are capturing market interest and driving market movements. 
Via Chartmill
Tech Sell-Off Rocks Wall Street: Nasdaq, S&P 500, and Dow Sink Amidst Brutal Week for Stocks
New York, NY – November 7, 2025 – The U.S. stock market has been gripped by a significant downturn in early November 2025, culminating in a brutal week that saw the Nasdaq Composite, S&P 500, and Dow... 
Via MarketMinute
Topics Artificial Intelligence Economy Retirement
The Weight-Loss Drugs Craze Is Going Strong. But Stock Investors Should Know A Few Things.
The feast that saw obesity-tied stocks skyrocket in 2024 is over. Investors' appetite for weight-loss drugs has waned. 
Via Investor's Business Daily
Topics Government
Sangamo (SGMO) Q3 2025 Earnings Call Transcript
Sangamo (SGMO) Q3 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
Famed Investor Michael Burry Bets Against Nvidia and Palantir to the Tune of $1.1 billion. Is He Right?
Burry is famous for shorting the market during the mortgage crisis. Is he going to win big again? 
Via The Motley Fool
Topics Artificial Intelligence
AI Unlocks Gene-Editing Revolution: $2 Million Grant Propels Disease Cures
A groundbreaking $2 million grant from the National Institutes of Health (NIH) is set to dramatically accelerate advancements in gene-editing technology, with artificial intelligence (AI) emerging as... 
Via TokenRing AI
Topics Artificial Intelligence Climate Change Intellectual Property
US Stocks Tumble Amid AI Valuation Fears and Mounting Job Worries
The U.S. stock market experienced a notable downturn today, November 6, 2025, as investors grappled with growing apprehension over the lofty valuations of artificial intelligence (AI) stocks and a... 
Via MarketMinute
Topics Artificial Intelligence Bonds Economy
Eli Lilly, Novo Nordisk Make Weight-Loss Drugs More Affordable Via Medicare, Medicaid, TrumpRx
The Trump administration struck deals with Eli Lilly and Novo Nordisk to lower obesity drug prices and expand Medicare coverage starting in 2026. 
Via Benzinga
Topics Government
Stay informed about the most active stocks in the S&P500 index on Thursday's session.
Stay informed about the most active S&P500 stocks in today's session as we take a closer look at what's happening on the US markets on Thursday. Discover the stocks that are generating the highest... 
Via Chartmill
3 Value Stocks That Fall Short
Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The key risk, however, is that these stocks are... 
Via StockStory
Pfizer To Raise Metsera Bid After Court Denies Attempt To Block Rival Deal
Delaware court denies Pfizer bid to block Metsera's Novo Nordisk deal as FTC flags antitrust risks and Pfizer prepares a higher counteroffer. 
Via Benzinga
Novo Nordisk Reportedly Refrains From Backing Down In Metsera Acquisition Battle, Sweetens Bid Further
According to an FT report, Pfizer now has two days to match Novo’s new bid or let its agreed-upon deal with Metsera fall through. 
Via Stocktwits
Ligand Pharmaceuticals Soars to New Heights: A Deep Dive into its 52-Week High
San Diego, CA – November 6, 2025 – Ligand Pharmaceuticals (NASDAQ: LGND) has recently captured the financial spotlight, with its stock hitting a remarkable 52-week high of $197.78 on November 6, 2025.... 
Via MarketMinute
Topics Intellectual Property
'It's Getting Ugly,' Analyst Says As Pfizer Escalates Its Gloves-Off Fight For Metsera
Metsera stock surged Thursday on reports Pfizer has matched Novo Nordisk's $10 billion bid to buy the obesity-focused biotech. 
Via Investor's Business Daily
Market Momentum Stalls: Valuations Under Scrutiny as Bullish Run Faces Headwinds
As November 2025 unfolds, the global stock markets find themselves at a critical juncture, struggling to reclaim the robust bullish momentum that characterized much of the preceding years. A palpable... 
Via MarketMinute
Topics Artificial Intelligence Economy World Trade
Viatris’s (NASDAQ:VTRS) Q3 Sales Top Estimates
Medication company Viatris (NASDAQ:VTRS) beat Wall Street’s revenue expectations in Q3 CY2025, but sales were flat year on year at $3.76 billion. The company’s full-year revenue guidance of $14.1... 
Via StockStory
Why Pfizer's 7%-Yielding Dividend Just Became Safer -- and More Tempting
Pfizer just gave income investors four reasons to like its juicy dividend even more. 
Via The Motley Fool
Topics Earnings Intellectual Property
2 Dirt Cheap Stocks to Buy With $1,000 Right Now
With big yields, these turnaround stocks look like they are attractively priced for those who can handle some uncertainty. 
Via The Motley Fool
Novo Nordisk Snaps 11-Day Losing Streak After Court Rejects Pfizer’s Challenge To $10B Metsera Deal
Delaware Chancery Judge Morgan Zurn ruled that Pfizer’s objections did not justify delaying Novo’s $10 billion acquisition of obesity-drug startup Metsera. 
Via Stocktwits
Topics Law Enforcement
US Economic Resilience Fuels Dollar's Ascent Amidst Global Shifts
The United States economy is currently riding a wave of positive momentum, with a series of robust economic indicators signaling underlying strength and resilience. This optimistic outlook has, in... 
Via MarketMinute
Topics Artificial Intelligence Bonds Economy
Navigating the Tempest: Market Consolidation Amidst Post-Slide Uncertainty
The financial markets, still reeling from a tumultuous period marked by significant downturns, are now grappling with an uneasy attempt at consolidation. As of November 5, 2025, investors are... 
Via MarketMinute
Topics Artificial Intelligence Bonds Economy
Obesity Drugmakers Face Shifting Tides: Novo Nordisk Plunges While Eli Lilly Soars
The burgeoning market for obesity and diabetes treatments, particularly GLP-1 receptor agonists, is witnessing a dramatic divergence in fortunes among its leading players. As of November 5, 2025, Novo... 
Via MarketMinute
Topics Economy
US Government Shutdown Casts a Shadow: Data Blackout and Market Jitters as Longest Shutdown Unfolds
The United States finds itself in an unprecedented economic fog as a prolonged government shutdown, now stretching well into its second month, has brought the flow of critical official data to a... 
Via MarketMinute
Topics Economy
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.